Survival Improving in Metastatic Bladder Cancer
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
The Cost of Bladder Cancer Care Is Rising. Could Value-Based Care Models Help?
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Radical Cystectomy Increases Risks for Thromboembolic Events
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Cost of Radical Cystectomy Higher in the West Than in Other US Regions
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Aortic Calcification Ups Risk for Acute Kidney Injury After Radical Cystectomy
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
Gemcitabine-Docetaxel Deemed Reasonable Alternative to BCG During Shortage
Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Opioid Prescription Can Be Eliminated After Urologic Cancer Surgery
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
Pembrolizumab Could Meet Unmet Need in BCG-Unresponsive High-Risk NMIBC
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
High Pretreatment NLR Signals Worse Outcomes in Muscle-Invasive Bladder Cancer
A high pretreatment neutrophil-to-lymphocyte ratio is associated with worse outcomes in patients with muscle-invasive bladder cancer, a study suggests.
ROS and Nerve-Sparing Radical Cystectomy May Be Underused in Women With Bladder Cancer
A survey of US urologic oncologists suggests that reproductive organ-sparing and nerve-sparing radical cystectomy may be underused in women with bladder cancer.
Genitourinary Cancer Incidence and Mortality Varies by Region, Race, and Sex
Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.
Efficacy of NMIBC Treatments After BCG Failure Characterized
A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and novel biologic agents.
Gene Therapy Approved for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
The FDA has approved the gene therapy Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.
Smoking Duration, Intensity Tied to Bladder Cancer Recurrence
Pipes, cigars, e-cigarettes, and marijuana were not tied to recurrence risk.
Complications Requiring Reoperation Common After Radical Cystectomy
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn
The decision to withdraw the indication was made based on findings from the phase 3 IMvigor130 trial.
Post-Cystectomy Long-Term Follow-Up Needed Even If No Sign of Bladder Cancer
Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.
Repeat TURBT Before RC Does Not Improve Bladder Cancer Outcomes
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...